key: cord-0950626-4jzvi0r3 authors: Yuan, Xueting; Tong, Xunliang; Wang, Yan; Wang, He; Wang, Liuming; Xu, Xiaomao title: Coagulopathy in elderly patients with coronavirus disease 2019 date: 2020-12-29 journal: Aging Med (Milton) DOI: 10.1002/agm2.12133 sha: 6f09c45b2860d4ff63192bdc12639be7f5eab6f2 doc_id: 950626 cord_uid: 4jzvi0r3 BACKGROUND: Since the outbreak of coronavirus disease 2019 (COVID‐19), clinical features have been analyzed in detail. However, coagulopathy in elderly COVID‐19 patients has been scarcely reported. METHODS: Coagulation parameters of 189 patients with COVID‐19 in Tongji hospital were retrospectively analyzed among age groups. RESULTS: Patients were divided into 2 groups: older group (≥65 years, n = 87) and younger group (<65 years, n = 102). The proportion of patients with elevated fibrinogen (79.0% vs 59.6%, p = .005) and D‐dimer (78.0% vs 55.2%, p = .001) shows the significant difference between the groups. The elderly patients revealed significantly longer prothrombin time (14.0 [13.4–14.4]s vs 13.6 [13.2–14.1]s, p = .026), higher D‐dimer (1.00 [0.5–1.9] μg/mL vs 0.6 [0.3–1.6] μg/mL, p = .013) and fibrinogen (5.2 [4.1–6.2] g/L vs 4.4 [3.4–5.7] g/L, p = .004) levels, compared to the younger group. A positive correlation was observed between the coagulation parameters and inflammatory markers including high‐sensitivity C‐reactive protein and interleukin‐6 (p < .05). CONCLUSIONS: The hypercoagulable state is more common in elderly COVID‐19 patients, and coagulopathy is associated with excessive systemic inflammation. with SARS-CoV-2 infection, and to investigate the relations between coagulopathy and systemic inflammation in COVID-19 patients. The clinical data, including demographics information; underlying diseases; laboratory results and clinical outcomes were extracted from electronic medical records. Coagulation tests included prothrombin time (PT), activated partial thromboplastin time (APTT), fibrinogen (FIB), platelet count (PLT) and D-dimer. High sensitivity C-reactive protein (hsCRP) and interleukin-6 (IL-6) as inflammatory markers were also detected. The data above were recorded in the first 24 hours after diagnosis. The end point was written of discharging from hospital or death. All the data were reviewed by experienced physicians separately and checked by two physicians independently. All measurements were expressed as median (interquartile range [IQR]) or number (%). Continuous variables were compared using the Mann-Whitney U test. Categorical variables were compared using the Chi-squared test. Correlations between variables were analyzed using the Spearman's rank correlation. A p-value < .05 was considered statistically significant. Data was analyzed using SPSS software (version 25.0). A total of 189 patients with severe COVID-19 were enrolled in this study. The median age was 59.2 years (range, 24-91 years) and 95 (50.3%) were male. 91(46.0%) patients had chronic underlying diseases, including chronic respiratory disease (6.3%), hypertension (41.5%), diabetes (34.8%), cardiovascular diseases (5.3%), cerebrovascular diseases (2.1%), tumors (3.2%), liver diseases (0.5%), and kidney diseases (3.2%). All patients were treated according to the pneumonia diagnosis protocol for novel coronavirus infection (trial version 7). 2 By the end of March 21, 2020, 178 patients (94.2%) were discharged and 11 (5.8%) died, including 6 cases in the older group and 5 cases in the younger group. Table 1 . According to the Consensus of Chinese experts on the diagnosis of disseminated intravascular coagulation (version 2017), 13 Coagulation system plays a crucial role in the innate immunity. 14 Multiple inhibitory pathways regulate the coagulation process, such as tissue factor pathway inhibitor (TFPI), antithrombin (AT), and protein C system. 15 The imbalance between coagulation and anticoagulation systems is responsible for abnormalities. Current evidence points to an extensive cross-talk between coagulation and inflammation systems. 16 COVID-19 infection has a heterogenous disease course, majority of patients only have mild symptoms, while some severe patients have immunologic complications, resulting in cytokine storm. 17 Inflammatory factors such as IL-1 and IL-6 promote a hypercoagulable state through excess thrombin generation and fibrinolysis shutdown. 18 Previous studies have asserted that advanced age is a risk factor in the development of VTE and that the incidence of VTE increases significantly with increasing age. 19 ,20 COVID-19 patients with coagulation dysfunction have a higher risk of death. 21 Therefore, coagulopathy in elderly COVID-19 patients need more clinical concern. Klok FA et al reported a VTE rate of 27% in severe COVID-19 patients, and pulmonary embolism (PE) was the most frequent thrombotic complication. 22 Elderly patients always have reduced physical mobility and high hospitalization rates for illnesses that contribute to the development of VTE. 20 In our study, we found higher D-dimer and FIB levels in the older group, which indicated that elderly COVID-19 patients tend to be in a hypercoagulable state and have higher risks of thromboembolism. Besides, longer PT was also observed in the older group compared to the younger group but both groups were within the normal reference range and did not belong to the pathological state of the disease, which Only 189 patients were included in our cohort due to the time and condition constraints. Nonetheless, our study has shown that the hypercoagulable state is more common in elderly COVID-19 patients, with the longer PT, higher D-dimer and FIB levels. HsCRP and IL-6 levels had significant correlations with coagulation parameters, which confirmed that coagulopathy is associated with excessive systemic inflammation. The monitoring of the coagulation function may be helpful to evaluate early prognosis in the elderly. The authors report no conflicts of interest related to the submitted work. All the data from electronic medical records in Tongji Hospital were reviewed by experienced physicians separately and checked by 2 physicians independently. Xueting Yuan https://orcid.org/0000-0002-0206-4273 Clinical characteristics of coronavirus disease 2019 in China Health Commission, PRC. The pneumonia diagnosis protocol for novel coronavirus infection The 2019-new coronavirus epidemic: evidence for virus evolution A novel coronavirus from patients with pneumonia in China Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome The nucleocapsid protein of SARS-CoV induces transcription of hfgl2 prothrombinase gene dependent on C/EBP alpha MERS-CoV infection in humans is associated with a pro-inflammatory Th1 and Th17 cytokine profile Middle east respiratory syndrome virus pathogenesis COVID-19 patients' clinical characteristics, discharge rate, and fatality rate of meta-analysis[J] Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China Significant age, race and gender differences in global coagulation assays parameters in the normal population In normal controls, both age and gender affect coagulability as measured by thrombelastography Hematology Society of Chinese Medical Association. Consensus of Chinese experts on diagnosis of disseminated intravascular coagulation (version 2017) Coagulation and innate immune responses: can we view them separately Blood coagulation: a powerful bactericidal mechanism of human innate immunity Crosstalk between inflammation and coagulation: the lessons of sepsis Cytokine storm in COVID-19: pathogenesis and overview of anti-inflammatory agents used in treatment Venous thrombosis in the elderly The epidemiology of venous thromboembolism in the community: implications for prevention and management Prominent changes in blood coagulation of patients with SARS-CoV-2 infection Incidence of thrombotic complications in critically ill ICU patients with COVID-19 Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy Correspondence Advances in the relationship between coronavirus infection and coagulation function Advances in the relationship between 2019-nCoV infection and coagulation function Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by Coronavirus-19 (COVI-19 or SARS-CoV-2): anti-inflammatory strategies Inflammation, endothelium, and coagulation in sepsis Coagulopathy in elderly patients with coronavirus disease 2019